Clinical trialNCT01757262WithdrawnPhase 3Interventional

A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient

SponsorAstraZenecaEnrollment0Coronary Heart Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Judith Hsia, MD
Astrazeneca, Wilmington, US
Study Director
clinicaltrials.gov ↗
Miriana Kujacic, MD
Astrazeneca, Molndal, Sweden
Study Chair
clinicaltrials.gov ↗
Nguyen Lan Viet, MD
National Heart Institute, Bach Mai Hospital, Vietnam
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

75mg ClopidogrelTicagrelor →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2013
Primary completion: 30 Apr 2013
Completion: 30 Apr 2013
Last update posted: 13 May 2013
Registered enrollment: 0
Registry id: NCT01757262

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.